Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Mouse C3 ELISA Kit (AC2781)
Cat.#: ASET-1370
Specifications
Description Mouse C3 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of mouse C3 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Mouse Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.25 µg/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 5-80 µg/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1762 Human GDF7 ELISA Kit (AC3173) Quantitative inquiry ASET-1525 Human beta Catenin ELISA Kit (AC2936) Quantitative inquiry ASET-1847 Mouse LRP1 ELISA Kit (AC3258) Quantitative inquiry ASET-2154 Human IMPA2 ELISA Kit (AC3565) Quantitative inquiry ASET-1547 Mouse Synaptophysin ELISA Kit (AC2958) Quantitative inquiry ASET-2201 Rat LC3B ELISA Kit (AC3612) Quantitative inquiry ASET-1595 Human SPTBN2 ELISA Kit (AC3006) Quantitative inquiry ASET-1967 Human Estrogen Receptor beta ELISA Kit (AC3378) Quantitative inquiry ASET-1119 Mouse Hes1 ELISA Kit (AC2530) Quantitative inquiry ASET-1073 Human FGFR4 ELISA Kit (AC2484) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket